The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
β blockers in hypertension and cardiovascular disease
Open accessAbstract
This review provides practical pointers on the use of β blockers for the non-specialist clinician
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“β-adrenergic antagonists, commonly known as β-blockers, are primarily used to manage cardiovascular conditions such as hypertension and coronary artery disease, and act by inhibiting β-adrenergic receptors (β-ARs) within the adrenergic system.323–325”
From Drug repurposing for cancer therapy (2024) · cites this paper as [325]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Hemodynamic Patterns of Age-Related Changes in Blood Pressure: The Framingham Heart Study
Franklin, S. S., Gustin, W., Wong, N. D., Larson, M. G., Weber, M. A., Kannel, W. B., & Levy, D. (1997) · Circulation · doi:10.1161/01.cir.96.1.308 · Cited by 2,321
beta Blockade after myocardial infarction: systematic review and meta regression analysis
Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J. (1999) · BMJ · doi:10.1136/bmj.318.7200.1730 · Cited by 1,509
Atenolol in hypertension: is it a wise choice?
Carlberg, B., Samuelsson, O., & Lindholm, L. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17355-8 · Cited by 562
Research works printed but not linked: 17
- Dahlof B, Sever PS, Poulter NR, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as require versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906.
- Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.
- Poulter NR, Wedel H, Dahlof B, for the ASCOT investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-13.
- Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the beta-blocker cholesterol-lowering asymptomatic plaque study (BCAPS). Circulation 2001;103:1721-6.
- CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353:9-13.
- MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
- Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
- MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
- First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS1. Lancet 1986;2:57-67.
- Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174:1737-42.
- Benetos A, Waeber B, Izzo J, et al. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness. Am J Hypertens 2002;15:1101-8.
- Resnick LM, Lester MH. Differential effects of antihypertensive drug therapy on arterial compliance. Am J Hypertens 2002;15:1096-100.
- Topol EJ. Arthritis medicines and cardiovascular events-"House of Coxibs". JAMA 2005;293:366-8.
- Poldermans D, Boersma E, Bax JJ, Thomson I, van de Ven L, Blankensteijn J, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high risk patients undergoing vascular surgery. Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group. N Engl J Med 1999;341:1789-94.
- Poldermans D, Boersma E, Bax JJ, Poldermans D, Boersma E, Bax JJ, et al. Dutch echocardiographic cardiac risk evaluation applying stress echocardiography study group. Bisoprolol reduces cardiac death and myocardial infarction in high risk patients as long as 2 years after successful major vascular surgery. Eur Heart J 2001;22:1353-8.
- Dahlof B, Devereux RB, Kjeldsen SE, Devereux RB, Beevers G, de Faire U, et al for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
- Julius S, Kjeldsen SE, Weber M, for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-31.
Cited by
Sorted by citations
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Metadata
- Authors
- Ong, H. T.
- Corresponding author
- Ong, H T
- ORCID
- Ong, H T
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2007-05-03
- Volume
- 334
- Issue
- 7600
- Pages
- 946-949
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- PMC
- PMC1865458
- OpenAlex
- W2075055511
- Cited by
- 61
- References
- 5
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 7 · 2019: 2 · 2018: 1 · 2017: 2 · 2015: 1 · 2014: 3 · 2013: 8 · 2012: 4
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- BMJ (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- beta-blockers, hypertension, cardiovascular disease, antihypertensive therapy, clinical management
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Antihypertensive Agents, Cardiovascular Diseases, Clinical Trials as Topic, Humans, Hypertension, Middle Aged, Meta-Analysis as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
